Baillie Gifford, an investment management firm, led a $300m Series D round in Zymergen, a science and material innovation company. Other investors that were involved in the transaction include Baron Capital Group, an asset management firm, and Perceptive Advisors, a hedge fund. "Our investment philosophy is to identify companies that can deliver transformational change over the long term. Zymergen is demonstrating their ability to create products at scale with properties that were previously unimaginable. Their rich and growing product pipeline, coupled with their platform approach, makes this a repeatable process that gets better over time. As long-term investors, we seek out companies with the potential to change industries over decades. Zymergen is such a company," Peter Singlehurst, Baillie Gifford Head of Unlisted Equities.